Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

102.95 -2.32 (-2.20%)
Streaming Delayed Price Updated: 3:20 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,568,282
Open 103.18
Bid (Size) 102.94 (3)
Ask (Size) 102.96 (7)
Prev. Close 105.27
Today's Range 101.51 - 103.22
52wk Range 94.73 - 148.15
Shares Outstanding N/A
Dividend Yield 1.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity? 
Via Benzinga
Are Diet Drug Companies Over The Hump?
Eli Lilly made a reversal bottom low on Monday after a gap lower. Today’s price action was confirmation. 
Via Talk Markets
Topics Stocks / Equities

Performance

YTD
+0.82%
+0.82%
1 Month
-12.26%
-12.26%
3 Month
-23.72%
-23.72%
6 Month
-23.19%
-23.19%
1 Year
+0.17%
+0.17%

More News

Read More
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
Via Benzinga
Is Novo Nordisk Stock a Buy Right Now?
Via The Motley Fool
Novo Nordisk Unusual Options Activity For November 19
Via Benzinga
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Via Benzinga
This Is What Whales Are Betting On Novo Nordisk
Via Benzinga
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Not-So-Big Pharma
Via Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Via The Motley Fool
Topics Government
Exposures Political
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Via Benzinga
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
Via Chartmill
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Via Benzinga
What's Going On With Hims & Hers Health Stock On Wednesday?
Via Benzinga
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Via Investor's Business Daily
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Via Benzinga
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance
Via MarketBeat
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Via Benzinga
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Via The Motley Fool
Is Viking Therapeutics a Buy on the Dip?
Via The Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.